BGI Genomics Co., Ltd.

Equities

300676

CNE100003449

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
38.92 ^CNY	-0.38%		+1.22%	-18.92%

Apr. 15	BGI Genomics Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Mar. 01	BGI Genomics' 2023 Profit Falls 89% as Revenue Plunges 38%	MT

BGI Genomics Co., Ltd. agreed to acquire 11% stake in Shenzhen Zaozhidao Technology CO., Ltd from Shenzhen Zaozhidao Investment Co., Ltd. and Shenzhen Cebuzhun Investment Enterprise (Limited Partnership) for CNY 18 million.

December 21, 2021

BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire 11% stake in Shenzhen Zaozhidao Technology CO., Ltd from Shenzhen Zaozhidao Investment Co., Ltd. and Shenzhen Cebuzhun Investment Enterprise (Limited Partnership) for CNY 18 million on December 22, 2021. The deal is subject to approval from BGI Genomics Co., Ltd. (SZSE:300676) board. As on December 22, 2021 BGI Genomics Co., Ltd. (SZSE:300676) board approved the deal.

For the year ended at September 30, 2021 Shenzhen Zaozhidao Technology CO., Ltd recorded the total assets of CNY 45 million and negative net assets of CNY 47 million.

Latest news about BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 15	CI
BGI Genomics' 2023 Profit Falls 89% as Revenue Plunges 38%	Feb. 29	MT
BGI Genomics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
China stocks rise further on market rescue hopes; HK flat	Feb. 06	RE
Wuxi AppTec Denies Ties to Military in Wake of US Draft Bill Targeting Chinese Biotech Firms	Feb. 05	MT
US bill targeting Chinese biotech firms WuXi AppTec, BGI hits delay	Feb. 02	RE
Correction: GemPharmatech Responds to US Legislation Concerns	Jan. 29	MT
Correction: Chinese Shares End Lower on US Draft Bill Targeting Chinese Biotech Firms; MGI Slumps 12%, Wuxi AppTec Falls 9%	Jan. 29	MT
GemPharmatech Responds to US Legislation Concerns	Jan. 29	MT
MGI Tech Responds to US BIOSECURE Act	Jan. 29	MT
Chinese Shares End Lower on US Draft Bill Targeting Chinese Biotech Firms; MGI Slumps 12%, Wuxi AppTec Falls 9%	Jan. 29	MT
US House bill would curb genetic info sharing with China's Wuxi Apptec, BGI	Jan. 26	RE
BGI Genomics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Chinese Shares Extend Losses as Bank Borrowing Plunges to 14-Year Low; BGI Falls 6% After M&A Announcement	23-08-14	MT
BGI Genomics to Acquire Health Management Firm; Shares Slump 6%	23-08-14	MT
BGI Genomics Co., Ltd. signed a share transfer agreement to acquire Shenzhen Huada Special Inspection Technology Co., Ltd. from Shenzhen BGI Hospital Management Holding Co., Ltd. for CNY 0.71 million.	23-08-11	CI
BGI Genomics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
BGI Genomics Appoints COO	23-06-30	MT
Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023	23-05-31	CI
Bgi Genomics Co., Ltd. Approves Cash Dividend for 2022	23-05-10	CI
BGI Genomics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
BGI Genomics Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-03-31	CI
BGI Genomics Co., Ltd. agreed to acquire 15.65% stake in BGI Shuji Biotechnology Co., Ltd. for CNY 55.2 million.	23-03-30	CI
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia	23-03-29	CI
China opposes U.S. adding Chinese firms to trade blacklist	23-03-03	RE

Chart BGI Genomics Co., Ltd.

Duration

Period

More charts

Company Profile

BGI Genomics Co., Ltd. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.

Sector

Biotechnology & Medical Research

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
BGI GENOMICS CO., LTD.	-18.92%	2.04B
EXACT SCIENCES CORPORATION	-20.53%	10.67B
IOVANCE BIOTHERAPEUTICS, INC.	+41.94%	3.22B
GUARDANT HEALTH, INC.	-36.56%	2.09B
VERACYTE, INC.	-29.19%	1.46B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+15.73%	1B
SEEGENE, INC.	-4.37%	734M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.73%	379M
CURIOX BIOSYSTEMS CO., LTD	+16.90%	343M

Bio Diagnostics & Testing